1. The study involved 160 older adults aged 60+.
2. Insomnia participants showed higher depressed mood post-inflammatory exposure.
3. Instruments used were POMS-D, MADRS, and HAM-D.
4. Significance in depressive symptoms was observed in participants with insomnia.
5. Endotoxin administered was low-dose (0.8 ng/kg IV).
6. No adverse events were reported during the trial.
7. Follow-up confirmed depression scores returned to baseline after 7 days.

Source: JAMA Psychiatry